EMA/182544/2019

European Medicines Agency decision

P/0121/2019

of 17 April 2019

on the acceptance of a modification of an agreed paediatric investigation plan for etravirine (Intelence), (EMEA-000222-PIP01-08-M09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0121/2019

of 17 April 2019

on the acceptance of a modification of an agreed paediatric investigation plan for etravirine (Intelence), (EMEA-000222-PIP01-08-M09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/10/2009 issued on 27 January 2009, the decision P/257/2009 issued on 23 December 2009, the decision P/110/2010 issued on 6 July 2010, the decision P/43/2011 issued on 11 February 2011, the decision P/129/2011 issued on 8 June 2011, the decision P/273/2011 issued on 28 October 2011, the decision P/0205/2012 issued on 7 September 2012, and the decision P/0162/2013 issued on 29 July 2013 and the decision P/0163/2015 issued on 7 August 2015,

Having regard to the application submitted by Janssen-Cilag International NV on 26 November 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 March 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for etravirine (Intelence), tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Janssen-Cilag International NV, Turnhoutseweg 30, 2340 – Beerse, Belgium.

EMA/PDCO/842287/2018
London, 1 March 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000222-PIP01-08-M09

Scope of the application

Active substance(s):

Etravirine

Invented name:

Intelence

Condition(s):

Treatment of Human Immunodeficiency Virus (HIV-1) Infection

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Janssen-Cilag International NV

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International NV submitted to the European Medicines Agency on 26 November 2018 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/10/2009 issued on 27 January 2009, the decision P/257/2009 issued on

23 December 2009, the decision P/110/2010 issued on 6 July 2010, the decision P/43/2011 issued on 11 February 2011, the decision P/129/2011 issued on 8 June 2011, the decision P/273/2011 issued on 28 October 2011, the decision P/0205/2012 issued on 7 September 2012, and the decision P/0162/2013 issued on 29 July 2013 and the decision P/0163/2015 issued on 7 August 2015.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 3 January 2019.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of Human immunodeficiency virus infection

The waiver applies to:

- the paediatric population from birth to less than 2 months;
- tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of human immunodeficiency virus infection

2.1.1. Indication(s) targeted by the PIP

Treatment of HIV-1 infection in antiretroviral treatment-experienced adolescents and children from 2 months to less than 18 years of age

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 months to less than 18 years

2.1.3. Pharmaceutical form(s)

Tablet

2.1.4. Studies

Area	Number of studies	Description
Quality	1	**Study 1** Development of a 25 mg scored tablet
Non-clinical	0	Not applicable.
Clinical	2	**Study 2** Open-label trial to evaluate the safety, tolerability and antiviral activity of etravirine in antiretroviral experienced HIV-1 infected children and adolescents from 6 years to less than 18 years of age. (TMC125-C213) **Study 3** Open-label trial to evaluate the safety, tolerability, pharmacokinetics and antiretroviral activity of etravirine in antiretroviral experienced HIV-1 infected children aged from 2 months to less than 6 years of age. (TMC125-TiDP35-C234/IMPAACT P1090)

3. Follow-up, completion and deferral of PIP

Concerns on potential long term issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2019
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s)

1. Treatment of Human Immunodeficiency Virus infection

Authorised indications:

- INTELENCE, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in antiretroviral treatment experienced adult patients and in antiretroviral treatment experienced paediatric patients from 6 years of age (see sections 4.4, 4.5 and 5.1);
- the indication in adults is based on week 48 analyses from 2 Phase III trials in highly pre-treated patients where INTELENCE was investigated in combination with an optimised background regimen (OBR) which included darunavir/ritonavir. The indication in paediatric patients is based on 48 week analyses of a single arm, Phase II trial in antiretroviral treatment experienced paediatric patients (see section 5.1).

Authorised pharmaceutical form(s)

Tablet

Authorised route(s) of administration

Oral use